Delia Rota‐Scalabrini

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

Marco Ladetto, Chiara Lobetti‐Bodoni, Barbara Mantoan et al. · Blood · 2013 · 93 citations · Full text

Medicine, Hematology, Immunology +17

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Alessandra Larocca, Vittorio Montefusco, Sara Bringhen et al. · Blood · 2013 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini et al. · Journal of Clinical Oncology · 2022 · 88 citations · Full text

Medicine, Hematology, Oncology +17

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

Roberto Mina, Pellegrino Musto, Delia Rota‐Scalabrini et al. · The Lancet Oncology · 2022 · 85 citations · Full text

Medicine, Hematology, Oncology +17

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

Alessandra Larocca, Francesca Bonello, Gianluca Gaïdano et al. · Blood · 2021 · 81 citations · Full text

Medicine, Geriatric Medicine, Oncology +12